Pure speculation on my part part 2
This one involves Dr. Chung , CURE again, Elto Pharma, EMOR, AMBS, Coeptis, THC, Cannabinoids CBD oral delivery and the combination of them
Elto Pharma, Inc. is developing eltoprazine, an oral small molecule 5HT1A/1B partial agonist in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), aggression in Alzheimer’s disease and adult attention deficit hyperactivity disorder (adult ADHD).
Quick facts
The drug has displayed good oral bioavailability,
It crosses the Blood brain barrier.
THC, Cannabinoids, CBD all cross the BB as well.
Not only do they cross there is a study that they can help others drugs pass as well
According to a new study recently published in the journal, Molecular Pharmaceutics, researchers discuss a process by which CBDs are used to enhance the ability of these "trojan horse" molecules to pass through the BBB. The study, conducted by Dr. Ana I. Torres-Suárez and colleagues
https://www.labroots.com/trending/cannabis-sc...in-barrier
With that, AMBS & Elto Pharma received this...
Elto Pharma, Inc. has received a notice of allowance from the European Patent Office (EPO) covering the use of eltoprazine and eltoprazine in combination with a number of chemical compounds, including cannabidiol (CBD) in the treatment of Parkinson’s disease and Parkinson’s disease levodopa-induced dyskinesia (PD-LID). Once issued, the patent will protect the use of eltoprazine in the treatment of Parkinson’s and PD-LID through 2034.
The notice of allowance from the EPO underscores the potential for eltoprazine in combination with CBD, or chemical compounds, to treat Parkinson’s disease,” said Gerald E. Commissiong, President & CEO of Amarantus and interim-CEO of Elto Pharma. “The potential for cannabinoid pharmaceuticals is rooted in their potentially synergistic effects with other traditional pharmaceutical compounds, such as eltoprazine. We are very pleased with this first notice of allowance that we’ve received from this international patent family, and we expect to receive many more in the months from jurisdictions around the world, including the United States.”
https://www.amarantus.com/news/press-releases...-notice-of
Back on NOVEMBER 28, 2018
Coeptis Pharma Enters into Agreement to Acquire Elto Pharma
https://www.amarantus.com/news/press-releases...lto-pharma
That never came to fruition.
The next partnership was going to be with EMOR last Fall.
11.11.2019
Originally including Eltoprazine
Amarantus has entered into a binding term sheet for Elto Pharma to license eltoprazine to Emerald Organic Products. The transaction is expected to close in the fourth quarter of 2019
https://www.emerald-organic.com/press-release...-holdings/
A Deal did close, but not including Elto Pharma
1.2.2020
Amarantus Completes Sublicense of ESS, MANF and PhenoGuard to Emerald Organic Products
"Amarantus and Emerald continue to negotiate a transaction for eltoprazine, a product development candidate under development by Elto Pharma, Inc., Amarantus’ joint venture with Psychogenics, Inc."
https://www.amarantus.com/news/press-releases...phenoguard
So, what happened to COEPTIS?
Last Fall a day later after EMOR originally signed a term sheet for Elto Pharma and about a year after COEPTIS & ELTO Pharma didn't happen, this happened
CURE Pharmaceutical [OTCQB:CURR] Takes First Step to Acquire Coeptis Pharmaceutical and its Combination Drug for Osteoarthritis Pain and Hypertension
On November 12, 2019, CURE Pharmaceutical Holding Corp. (the “Company”) purchased a $200,000 convertible promissory note (the “Convertible Promissory Note”) issued by Coeptis Pharnaceuticals, Inc., a Delaware corporation, a privately held biopharmaceutical company engaged in the acquisition, development and commercialization of pharmaceutical products (“Coeptis”).
The Convertible Promissory Note is due June 15, 2020, pays interest at the rate of 9% per annum and gives the holder the right, at any time from the date thereof, to convert the Convertible Promissory Note into shares of common stock of Coeptis at a price per share equal to $2.60 (the “Optional Conversion Price”) or the share price set by the latest qualified financing, whichever is less.
In addition, on November 9, 2019, the Company and Coeptis entered into a non-binding term sheet contemplating that the Company and Coeptis will enter into a Merger Agreement pursuant to which a wholly-owned subsidiary of the Company will merge into Coeptis so that Coeptis will become a wholly-owned subsidiary of the Company with the final terms and valuation to be determined based on certain contingent events.
https://app.quotemedia.com/data/downloadFilin...CK=1643301
So, remember Dr. Chung who is now on the BOD at TODOS, serves on the business review board of Alzheimer’s Drug Discovery Foundation and is a Director at CURE and two of CURE's products are...
CUREform™ is our patented drug delivery platform. It includes CUREfilm®, one of the most advanced oral thin films on the market today; microCURE™, a proprietary emulsion technology; and CUREpods™ a novel chewable delivery system. CUREform's combined technologies provide opportunities for both immediate and controlled-release drug delivery of a wide range of active ingredients.
CUREfilm™ Hemp delivers hemp extracts via our CUREfilm® dosage form. This product is launched in U.S. markets.
CUREfilm® Canna delivers synthetic and plant-derived cannabinoids in an oral thin film for pharmaceutical indications.
And around that same time last FALL,
EMOR entered into an exclusive agreement with PetVivo whose main product is...
New York, NY, Aug. 05, 2019 (GLOBE NEWSWIRE) — Emerald Organic Products, Inc. (OTC:EMOR) (“Emerald” or the “Company”) is pleased to announce that it has formally entered into an exclusive licensing agreement for the use of OraPatch™, a patented oral delivery method for various substances including caffeine and cannabidiol (“CBD”) from PetVivo Holdings, Inc. (OTC
ETV) (“PetVivo”).
The patented oral adhesion technology, OraPatch™, is a slowly degradable protein wafer-disc that attaches to and assimilates with the mouth’s inner lining. PetVivo is the holder of patents for this unique and cutting-edge method for nutraceutical and supplement delivery.
The fully dissolving wafer-like invention sticks strongly and comfortably the roof of the mouth, cheeks, or gums. This delivery method provides both a rapid release and greater bioavailability when compared to ingestion. Furthermore, the OraPatch product only uses materials deemed to be Generally Recognized as Safe (“GRAS”) by the United States Food and Drug Administration (the “FDA”).
https://www.emerald-organic.com/press-release...dings-inc/
How this plays out, I haven't a clue.
I dont know where Elto Pharma will eventually end up, but there's quite a lot of activity around all those related companies and connections.
What it's going to involve, well it's looking pretty clear what is being aimed for.
For sure Gerald seems to be aiming for some really big moves with ELTOPRAZINE, CBD, possibly THC and oral administration.
This is while Todos is setting up for a NASDAQ Uplist, finalizing 2 acquisitions and delivering massively on a suite of CORONAVIRUS tests all in Q2.
This one involves Dr. Chung , CURE again, Elto Pharma, EMOR, AMBS, Coeptis, THC, Cannabinoids CBD oral delivery and the combination of them
Elto Pharma, Inc. is developing eltoprazine, an oral small molecule 5HT1A/1B partial agonist in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), aggression in Alzheimer’s disease and adult attention deficit hyperactivity disorder (adult ADHD).
Quick facts
The drug has displayed good oral bioavailability,
It crosses the Blood brain barrier.
THC, Cannabinoids, CBD all cross the BB as well.
Not only do they cross there is a study that they can help others drugs pass as well
According to a new study recently published in the journal, Molecular Pharmaceutics, researchers discuss a process by which CBDs are used to enhance the ability of these "trojan horse" molecules to pass through the BBB. The study, conducted by Dr. Ana I. Torres-Suárez and colleagues
https://www.labroots.com/trending/cannabis-sc...in-barrier
With that, AMBS & Elto Pharma received this...
Elto Pharma, Inc. has received a notice of allowance from the European Patent Office (EPO) covering the use of eltoprazine and eltoprazine in combination with a number of chemical compounds, including cannabidiol (CBD) in the treatment of Parkinson’s disease and Parkinson’s disease levodopa-induced dyskinesia (PD-LID). Once issued, the patent will protect the use of eltoprazine in the treatment of Parkinson’s and PD-LID through 2034.
The notice of allowance from the EPO underscores the potential for eltoprazine in combination with CBD, or chemical compounds, to treat Parkinson’s disease,” said Gerald E. Commissiong, President & CEO of Amarantus and interim-CEO of Elto Pharma. “The potential for cannabinoid pharmaceuticals is rooted in their potentially synergistic effects with other traditional pharmaceutical compounds, such as eltoprazine. We are very pleased with this first notice of allowance that we’ve received from this international patent family, and we expect to receive many more in the months from jurisdictions around the world, including the United States.”
https://www.amarantus.com/news/press-releases...-notice-of
Back on NOVEMBER 28, 2018
Coeptis Pharma Enters into Agreement to Acquire Elto Pharma
https://www.amarantus.com/news/press-releases...lto-pharma
That never came to fruition.
The next partnership was going to be with EMOR last Fall.
11.11.2019
Originally including Eltoprazine
Amarantus has entered into a binding term sheet for Elto Pharma to license eltoprazine to Emerald Organic Products. The transaction is expected to close in the fourth quarter of 2019
https://www.emerald-organic.com/press-release...-holdings/
A Deal did close, but not including Elto Pharma
1.2.2020
Amarantus Completes Sublicense of ESS, MANF and PhenoGuard to Emerald Organic Products
"Amarantus and Emerald continue to negotiate a transaction for eltoprazine, a product development candidate under development by Elto Pharma, Inc., Amarantus’ joint venture with Psychogenics, Inc."
https://www.amarantus.com/news/press-releases...phenoguard
So, what happened to COEPTIS?
Last Fall a day later after EMOR originally signed a term sheet for Elto Pharma and about a year after COEPTIS & ELTO Pharma didn't happen, this happened
CURE Pharmaceutical [OTCQB:CURR] Takes First Step to Acquire Coeptis Pharmaceutical and its Combination Drug for Osteoarthritis Pain and Hypertension
On November 12, 2019, CURE Pharmaceutical Holding Corp. (the “Company”) purchased a $200,000 convertible promissory note (the “Convertible Promissory Note”) issued by Coeptis Pharnaceuticals, Inc., a Delaware corporation, a privately held biopharmaceutical company engaged in the acquisition, development and commercialization of pharmaceutical products (“Coeptis”).
The Convertible Promissory Note is due June 15, 2020, pays interest at the rate of 9% per annum and gives the holder the right, at any time from the date thereof, to convert the Convertible Promissory Note into shares of common stock of Coeptis at a price per share equal to $2.60 (the “Optional Conversion Price”) or the share price set by the latest qualified financing, whichever is less.
In addition, on November 9, 2019, the Company and Coeptis entered into a non-binding term sheet contemplating that the Company and Coeptis will enter into a Merger Agreement pursuant to which a wholly-owned subsidiary of the Company will merge into Coeptis so that Coeptis will become a wholly-owned subsidiary of the Company with the final terms and valuation to be determined based on certain contingent events.
https://app.quotemedia.com/data/downloadFilin...CK=1643301
So, remember Dr. Chung who is now on the BOD at TODOS, serves on the business review board of Alzheimer’s Drug Discovery Foundation and is a Director at CURE and two of CURE's products are...
CUREform™ is our patented drug delivery platform. It includes CUREfilm®, one of the most advanced oral thin films on the market today; microCURE™, a proprietary emulsion technology; and CUREpods™ a novel chewable delivery system. CUREform's combined technologies provide opportunities for both immediate and controlled-release drug delivery of a wide range of active ingredients.
CUREfilm™ Hemp delivers hemp extracts via our CUREfilm® dosage form. This product is launched in U.S. markets.
CUREfilm® Canna delivers synthetic and plant-derived cannabinoids in an oral thin film for pharmaceutical indications.
And around that same time last FALL,
EMOR entered into an exclusive agreement with PetVivo whose main product is...
New York, NY, Aug. 05, 2019 (GLOBE NEWSWIRE) — Emerald Organic Products, Inc. (OTC:EMOR) (“Emerald” or the “Company”) is pleased to announce that it has formally entered into an exclusive licensing agreement for the use of OraPatch™, a patented oral delivery method for various substances including caffeine and cannabidiol (“CBD”) from PetVivo Holdings, Inc. (OTC
ETV) (“PetVivo”). The patented oral adhesion technology, OraPatch™, is a slowly degradable protein wafer-disc that attaches to and assimilates with the mouth’s inner lining. PetVivo is the holder of patents for this unique and cutting-edge method for nutraceutical and supplement delivery.
The fully dissolving wafer-like invention sticks strongly and comfortably the roof of the mouth, cheeks, or gums. This delivery method provides both a rapid release and greater bioavailability when compared to ingestion. Furthermore, the OraPatch product only uses materials deemed to be Generally Recognized as Safe (“GRAS”) by the United States Food and Drug Administration (the “FDA”).
https://www.emerald-organic.com/press-release...dings-inc/
How this plays out, I haven't a clue.
I dont know where Elto Pharma will eventually end up, but there's quite a lot of activity around all those related companies and connections.
What it's going to involve, well it's looking pretty clear what is being aimed for.
For sure Gerald seems to be aiming for some really big moves with ELTOPRAZINE, CBD, possibly THC and oral administration.
This is while Todos is setting up for a NASDAQ Uplist, finalizing 2 acquisitions and delivering massively on a suite of CORONAVIRUS tests all in Q2.
3
